ISDA

Deposition Date 2020-02-05

Release Date 2020-04-08

Last Version Date 2023-10-11

Entry Detail

PDB ID:

6VQF

Keywords:

TRANSCRIPTION

Title:

CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244- 487)-L6-SRC1(678-692)) IN COMPLEX WITH AN INVERSE AGONIST

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.24

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Nuclear receptor ROR-gamma
Gene (Uniprot):RORC
Chain IDs:A
Chain Length:285
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P51449 Pfam ID:PF00104

Ligand Molecules

GOL

R7V

Primary Citation

Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR gamma t Inverse Agonist.

Cherney, R.J, Cornelius, L.A.M, Srivastava, A, Weigelt, C.A, Marcoux, D, Duan, J.J, Shi, Q, Batt, D.G, Liu, Q, Yip, S, Wu, D.R, Ruzanov, M, Sack, J, Khan, J, Wang, J, Yarde, M, Cvijic, M.E, Mathur, A, Li, S, Shuster, D, Khandelwal, P, Borowski, V, Xie, J, Obermeier, M, Fura, A, Stefanski, K, Cornelius, G, Tino, J.A, Macor, J.E, Salter-Cid, L, Denton, R, Zhao, Q, Carter, P.H, Dhar, T.G.M.Show

Acs Med.Chem.Lett. 11 1221 1227 (2020)

PMID: 32551004 DOI: 10.1021/acsmedchemlett.0c00063

Abstact

Novel tricyclic analogues were designed, synthesized, and evaluated as RORγt inverse agonists. Several of these compounds were potent in an IL-17 human whole blood assay and exhibited excellent oral bioavailability in mouse pharmacokinetic studies. This led to the identification of compound 5, which displayed dose-dependent inhibition of IL-17F production in a mouse IL-2/IL-23 stimulated pharmacodynamic model. In addition, compound 5 was studied in mouse acanthosis and imiquimod-induced models of skin inflammation, where it demonstrated robust efficacy comparable to a positive control. As a result of this excellent overall profile, compound 5 (BMS-986251) was selected as a clinically viable developmental candidate.

Legend

Protein

Chemical

Disease

Primary Citation of related structures